Company: BDRX
Filing Date: 2025-12-08
Form Type: F-1/A
Source: 0001214659-25-017719
Chunk: 27

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-12-08
Form: F-1/A
Chunk 27
---
 the staff of NASDAQ, or the Staff. The Staff may provide
us with a 180-calendar day grace period to regain compliance with the bid price requirement. If we are unable to regain compliance with
the bid price requirement within the 180-calendar day grace period or if no grace period is made available to us, we may be delisted from
The NASDAQ Capital Market unless we change the ratio of our Depositary Shares to Ordinary Shares; however, there can be no assurance that
we will be able to change the ratio of our Depositary Shares to Ordinary Shares or that, if we are able to change the ratio, changing
the ratio of our Depositary Shares to Ordinary Shares will allow us to regain compliance with the bid price requirement. We currently
do not have plans to change the ratio of our Depositary Shares to Ordinary Shares or to implement a reverse stock split with respect to
our Ordinary Shares.

Additionally,
in the event of a delisting notice, we would typically have an opportunity to appeal such decision to the NASDAQ Hearing Panel or take
other measures to preserve the listing of our Depositary Shares on The NASDAQ Capital Market, but these measures and any appeal may not
be successful. If our Depositary Shares are delisted by NASDAQ, our Depositary Shares may be eligible to trade on an over-the-counter
quotation system, where an investor may find it more difficult to sell our Depositary Shares or obtain accurate quotations as to the market
value of our Depositary Shares. We cannot ensure that our Depositary Shares, if delisted from The NASDAQ Capital Market, will be listed
on any national securities exchange or quoted on an over-the counter quotation system.

In
the event we are delisted from The NASDAQ Capital Market, the only established trading market for our Depositary Shares would be eliminated,
and we would be forced to list our shares on the OTC Markets or another quotation medium, depending on our ability to meet the specific
listing requirements of those quotation systems. As a result, an investor would likely find it more difficult to trade or obtain accurate
price quotations for our Depositary Shares. Delisting would likely also reduce the visibility, liquidity, and value of our Depositary
Shares, reduce institutional investor interest in our company, and may increase the volatility of our Depositary Shares. Delisting could
also cause a loss of confidence of potential industry partners, lenders, and employees, which could further harm our business and our
future prospects.

Unless
our Depositary Shares